Compare JOE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | MLYS |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | JOE | MLYS |
|---|---|---|
| Price | $58.87 | $37.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 233.5K | ★ 1.5M |
| Earning Date | 10-29-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 53.79 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $488,689,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.69 | ★ N/A |
| Revenue Growth | ★ 26.89 | N/A |
| 52 Week Low | $40.19 | $8.24 |
| 52 Week High | $63.13 | $47.65 |
| Indicator | JOE | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 43.16 |
| Support Level | $60.78 | $36.50 |
| Resistance Level | $63.13 | $38.23 |
| Average True Range (ATR) | 1.37 | 1.68 |
| MACD | -0.55 | 0.09 |
| Stochastic Oscillator | 15.04 | 41.96 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.